A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

NCT05197153 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

804

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Vaccine

Interventions

BIOLOGICAL: Half dose of MVC-COV1901
BIOLOGICAL: Full dose of MVC-COV1901
BIOLOGICAL: AZD1222
BIOLOGICAL: Half dose of mRNA-1273

Sponsor

Medigen Vaccine Biologics Corp.

Collaborators

[object Object]